Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests and a new score may forecast brain bleed recovery

NCT ID NCT07728734

Knowledge-focused Sponsor: Germans Trias i Pujol Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether a new scoring system, called PRO-ICH, can accurately predict how well people will recover after a spontaneous brain hemorrhage. Researchers will also check if adding certain blood markers improves the score's accuracy. The goal is to give doctors a reliable way to estimate a patient's long-term functional outcome within the first hours of hospital care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a reliable tool to predict recovery after a brain hemorrhage, helping guide treatment decisions and reduce uncertainty for families.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. The scale may not prove accurate enough in real-world settings, and new blood biomarkers may add little benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,688 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive patients with spontaneous intracraneal hemorrhage admitted in several Comprehensive Stroke Center of different regions of Spain

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients ≥ 18 years diagnosed with spontaneous intracranial hemorrhage (ICH) by CT scan and treated maximally within the first 24 hours. 2. Prior functional independence defined as modified Rankin scale (mRS) ≤ 3. 3. Time from symptom onset or last known seen well ≤ 24 hours. 4. Signed informed consent by the patient or their representative. Exclusion Criteria: 1. Age \< 18 years 2. Intracranial hemorrhage secondary to trauma, ischemic stroke, or fibrinolytic or endovascular treatment. 3. Spontaneous ICH with limitation of therapeutic effort (LTE) within the first 24 hours. LTE is defined as the withholding or withdrawal of potentially life-sustaining treatment and/or the initiation of comfort care measures with the expectation that the patient may die as a result. Potentially life-sustaining treatments include: orotracheal intubation and mechanical ventilation, cardiopulmonary resuscitation, and neurosurgical treatments (intracranial pressure monitoring, external ventricular drainage, hematoma evacuation, decompressive craniectomy). LTE is not considered to apply if only a do-not-resuscitate (DNR) order was established, without limitation of any other treatment. 4. Prior functional dependence, defined as mRS \> 3 5. Time from symptom onset or last known seen well \>24 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial hemorrhage, spontaneous are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage Intracranial Hemorrhages

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracranial hemorrhage, spontaneous

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Neurology Department, German Trias I Pujol Hospital.

    Badalona, Barcelona, 08916, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.